The headline proclaimed "Anti-smoking drug Champix does not raise risk of suicide or depression."
This was a reference to a study published last September by Daniel Kotz and his colleagues in Lancet Respiratory Medicine, which compared the cardiovascular and neuropsychiatric risks of Chantix with two other stop smoking drugs: bupropion (trade name Zyban) and nicotine replacement therapy, or NRT.
The generic name for Chantix is varenicline. Outside the United states, varenicline is marketed as Champix.
